Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo aims to fight tough bladder cancer without removing bladder

NCT ID NCT07424287

First seen Feb 23, 2026 · Last updated May 23, 2026 · Updated 16 times

Summary

This phase 3 study tests whether a new drug (SHR-1501) given with BCG therapy works better than chemotherapy for people with a high-risk bladder cancer that has not responded to BCG alone. About 236 adults who cannot or choose not to have their bladder removed will take part. The main goal is to see how long the cancer stays away.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NMIBC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School

    Shanghai, Shanghai Municipality, 200120, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.